
David Cook appointed chief financial officer of Biotie
pharmafile | January 7, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Biotie, David Cook
David Cook has been appointed chief financial officer (CFO) of drug development firm Biotie Therapies and will become a member of the Group’s management team.
Reporting to Timo Veromaa, president and chief executive, Cook will be based at the company’s headquarters in Turku, Finland. Kristian Rantala, current interim CFO, will resume his prior duties as vice president, Finance and Administration.
Cook, a British native, has extensive industry expertise in life science enterprises in finance, strategy, investor relations and M&A. Previously Cook was CFO, International, of Jazz Pharmaceuticals, a NASDAQ listed company and before this CFO of EUSA Pharma Inc, which was acquired by Jazz Pharmaceuticals in mid-2012.
Prior to joining EUSA Cook was Group financial controller at Zeneus Pharma, and previously worked for PricewaterhouseCoopers in the UK and Australia.
Veromaa said: “I am very pleased that David is joining Biotie’s management team and we look forward to his contributions to the growth of the group. As Biotie continues to mature as a company, David’s extensive experience in building profitable biotech businesses will be extremely valuable.”
Related Content
Lundbeck to file alcoholism pill this year
Lundbeck plans to submit its alcohol dependency treatment for European approval later this year after …






